Mechanisms of FGFR3 actions in endocrine resistant breast cancer

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2857-2866

  Tomlinson, D C ^a   Knowles, M A ^a   Speirs, V ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

AKT; FGFR3; MAPK; phospholipase C; tamoxifen resistance

Indexed keywords

ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; TAMOXIFEN;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STIMULATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; ENDOCRINE RESISTANT BREAST CANCER; ENZYME ACTIVATION; ENZYME REGULATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOLIPASE C GAMMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84858396997     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26304     Document Type: Article

References (50)

1. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN,. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513-29.
2. Osborne CK,. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer 1999; 6: 271-6. (Pubitemid 29260063)
3. Howell A, Osborne CK, Morris C, Wakeling AE,. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000; 89: 817-25. (Pubitemid 30658581)
4. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH,. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002; 97: 306-12.
5. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI,. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144: 1032-44. (Pubitemid 36262870)
6. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M,. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003; 278: 30458-68. (Pubitemid 36994549)
7. Gee JM, Robertson JF, Ellis IO, Nicholson RI,. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-54. (Pubitemid 32592092)
8. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI,. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005; 12 (Suppl 1): S99-S111. (Pubitemid 41395417)
9. Daphna-Iken D, Shankar DB, Lawshe A, Ornitz DM, Shackleford GM, MacArthur CA,. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia. Oncogene 1998; 17: 2711-7. (Pubitemid 28554230)
10. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE,. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010; 70: 4151-62.
11. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D, deLapeyriere O,. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995; 61: 170-6.
12. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006; 12: 6652-62. (Pubitemid 44876833)
13. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-94.
14. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM,. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 2002; 157: 703-14. (Pubitemid 34839797)
15. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870-4. (Pubitemid 47014500)
16. Zammit C, Barnard R, Gomm J, Coope R, Shousha S, Coombes C, Johnston C,. Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol 2001; 194: 27-34.
17. Sahlin P, Tarnow P, Martinsson T, Stenman G,. Germline mutation in the FGFR3 gene in a TWIST1-negative family with saethre-chotzen syndrome and breast cancer. Genes Chromoson and cancer 2009; 48: 285-88.
18. Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC,. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 2008; 15: 101-11. (Pubitemid 351449731)
19. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N,. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747-55. (Pubitemid 46622313)
20. Eswarakumar VP, Lax I, Schlessinger J,. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-49. (Pubitemid 40616112)
21. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB, Kern FG,. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 1993; 53: 2168-77. (Pubitemid 23145744)
22. Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IY, Hanfelt J, McLeskey SW, Kern FG,. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997; 15: 2093-108. (Pubitemid 27489136)
23. Scott DJ, Parkes AT, Ponchel F, Cummings M, Poola I, Speirs V,. Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol 2007; 31: 557-65.
24. Tomlinson DC, L'Hote CG, Kennedy W, Pitt E, Knowles MA,. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 2005; 65: 10441-9. (Pubitemid 41743738)
25. Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM, Speirs V,. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 2008; 14: 405-11. (Pubitemid 351226107)
26. Tomlinson DC, Hurst CD, Knowles MA,. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007; 26: 5889-99.
27. di Martino E, L'Hote CG, Kennedy W, Tomlinson DC, Knowles MA,. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 2009; 28: 4306-16.
28. Limer JL, Parkes AT, Speirs V,. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J Cancer 2006; 119: 515-21. (Pubitemid 43955703)
29. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM,. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 2005; 171: 663-73. (Pubitemid 41668725)
30. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM, Spencer DM,. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res 2003; 63: 8256-63. (Pubitemid 37549476)
31. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM,. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007; 12: 559-71. (Pubitemid 350199071)
32. Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM,. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res; 70: 4868-79.
33. Mohammadi M, Dionne CA, Li W, Li N, Spivak T, Honegger AM, Jaye M, Schlessinger J,. Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature 1992; 358: 681-4.
34. Jacquemier J, Adelaide J, Parc P, Penault-Llorca F, Planche J, deLapeyriere O, Birnbaum D,. Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer 1994; 59: 373-8. (Pubitemid 24331829)
35. McLeskey SW, Zhang L, El-Ashry D, Trock BJ, Lopez CA, Kharbanda S, Tobias CA, Lorant LA, Hannum RS, Dickson RB, Kern FG,. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. Clin Cancer Res 1998; 4: 697-711. (Pubitemid 28193571)
36. Levenson AS, Jordan VC,. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997; 57: 3071-8. (Pubitemid 27351713)
37. Manuvakhova M, Thottassery JV, Hays S, Qu Z, Rentz SS, Westbrook L, Kern FG,. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. Oncogene 2006; 25: 6003-14. (Pubitemid 44477294)
38. Ehrhard KN, Jacoby JJ, Fu XY, Jahn R, Dohlman HG,. Use of G-protein fusions to monitor integral membrane protein-protein interactions in yeast. Nat Biotechnol 2000; 18: 1075-9.
39. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL,. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA 1991; 88: 10435-9. (Pubitemid 21915850)
40. Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M, Lattanzio R, Piantelli M, Iacobelli S, Broggini M, et al. Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 2008; 68: 10187-96.
41. Smith MR, Court DW, Kim HK, Park JB, Rhee SG, Rhim JS, Kung HF,. Overexpression of phosphoinositide-specific phospholipase Cgamma in NIH 3T3 cells promotes transformation and tumorigenicity. Carcinogenesis 1998; 19: 177-85. (Pubitemid 28376841)
42. Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S, Falasca M,. The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene 2002; 21: 6520-9. (Pubitemid 35155456)
43. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H,. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-24.
44. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D,. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001; 15: 1344-59. (Pubitemid 32703482)
45. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI,. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003; 81: 81-93. (Pubitemid 37108443)
46. Kurokawa H, Arteaga CL,. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003; 9: 511S-5S. (Pubitemid 36105795)
47. Ehrhardt A, David MD, Ehrhardt GR, Schrader JW,. Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. Mol Cell Biol 2004; 24: 6311-23. (Pubitemid 38891132)
48. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW,. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. Cancer Res 1999; 59: 5475-8. (Pubitemid 29526460)
49. Wang Y, Wang Z,. Regulation of EGF-induced phospholipase C-gamma1 translocation and activation by its SH2 and PH domains. Traffic 2003; 4: 618-30. (Pubitemid 37062685)
50. Wang Y, Wu J, Wang Z,. Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol Biol Cell 2006; 17: 2267-77. (Pubitemid 44011742)